Navigation Links
Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
Date:1/31/2008

AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused biopharmaceutical product development company Kiadis Pharma announced today that it has successfully finalized its Rhitol(TM) Phase II clinical trial with the last patient completing its six month treatment cycle. Rhitol(TM) is evaluated as treatment for patients with extensive chronic Graft versus Host Disease (GvHD) intolerant or resistant to standard immunosuppressive treatment.

The current preliminary clinical results demonstrate an excellent safety profile for Rhitol(TM) and evidence of efficacy in the alleviation of the symptoms associated with chronic Graft versus Host Disease. After this clinical study was closed for enrollment mid 2007 Kiadis Pharma allowed new patients to be treated under a compassionate protocol. The successful completion of the Phase II clinical trial of Rhitol(TM) paves the way for a phase III study and Kiadis Pharma is planning to file for a phase III multi center clinical trial in the USA and Canada within the next few months.

Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the positive outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic GvHD resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop into a life-threatening condition."

To read the complete press releases please go to http://www.kiadis.com

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Finding might one day lead to a novel technique t...AY, Nov. 21 (HealthDay News) -- Belgian researcher...c acid instead of sugar for food, and this might l...ells. , To survive and proliferate, all cells i... burning sugar [glucose], a process that requires ...
(Date:11/21/2008)... 11.4% Shareholders Intend To Vigorously Protect I... CINCINNATI, Nov. 21 Dr...y filed an amendment to their Schedule 13D with th...oup previously filed a 13D disclosing ownership of...h operates 77 LasikPlus fixed-site laser vision co...
(Date:11/21/2008)... MONTVALE, N.J., Nov. 21 ...nnounced that its shareholders overwhelmingly appr...he acquisition of Barr by Teva Pharmaceuticals Ind...,s vote demonstrated the overwhelming support of t...ce L. Downey, Barr,s Chairman and CEO. "We are ple...
(Date:11/21/2008)... DALLAS, Nov. 21 In a statewide su...e Texas Institute for Surgery at Presbyterian Hosp...its 2008 annual listing of " Super Doctors ." , ... work with Key Professional Media, Inc. to survey... state of Texas to ask, "If you needed medical car...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...aunching a cancer-fighting tomato. The supermarket...the Vine is lycopene-rich to the tune of almost tw...the chemical that gives red color to the tomatoes ...osed to fight prostate cancer, breast cancer and c...
...o was convicted of murdering Lin Russell and her s... publication of a report that probes the failure o...ng spree. // The independent report by Robert Fran...nce it was published six years ago after many appe...
...officials confirmed that a poultry worker in West ...ing the number of human cases in Indonesia to 33//...eceived the confirmation from WHO Tuesday morning,...eral of animal-borne disease control at the Indone...
...es like New York are sometimes good from far but f..., money, opportunity and over all a good life// , ...ts residents. According to a latest survey, New Yo... lot compared to the other parts of United States....
Other Medicine News:
(Date:11/20/2008)...November 20 Arpida (SWX:...ugs Advisory Committee of the,U.S. Food and Drug ...,approval of intravenous iclaprim, an antibiotic ...ients with complicated skin and skin structure inf...cillin-resistant Staphylococcus,aureus (MRSA). ,...
(Date:11/20/2008)...0 Bionovo, Inc.,(Nasdaq...lts from the Phase 1B,clinical trial of their lea...ancer, BZL101, at the Society for Integrative Onco... Georgia. The Company,s oral presentation was sel...nted as a part of the Best of the,SIO Session on ...
(Date:11/20/2008)... Radius Health ("Radius") announced...n to its second institutional financing round, inc... and the total amount raised since the company,s i...onal investors participated in the financing, led ... Capital, The Wellcome Trust, HealthCare Ventures,...
(Date:11/20/2008)...e-FirstCall/ -- PAREXEL International Corporation ...cal services provider, today announced that it has...ory consulting and clinical research capabilities.... has locations throughout five important biopharma...ude Argentina, Brazil, Chile, and Mexico. This exp...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Emageon Receives Best in KLAS Cardiology PACS Award 15216 1Emageon Receives Best in KLAS Cardiology PACS Award 15216 2QMed Inc Reports Year End and Fourth Quarter Results 15213 1QMed Inc Reports Year End and Fourth Quarter Results 15213 2QMed Inc Reports Year End and Fourth Quarter Results 15213 3QMed Inc Reports Year End and Fourth Quarter Results 15213 4QMed Inc Reports Year End and Fourth Quarter Results 15213 5QMed Inc Reports Year End and Fourth Quarter Results 15213 6QMed Inc Reports Year End and Fourth Quarter Results 15213 7Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 1Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 2NCPA Statement on Californias Delay of E Pedigree Implementation 15207 1NCPA Statement on Californias Delay of E Pedigree Implementation 15207 2
...LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceutic...inary results from its,phase II/III study with CB-...ea. CB-01-11 is a broad spectrum, semi-synthetic,a...t form. Through,the use of Cosmo,s MMX(tm) technol... colon, bacteria in the gastro intestinal tract,th...
...is weeks issue of Science,researchers from the Na...(NIEHS) and Umeö University in Sweden report ...hat an enzyme called,DNA polymerase epsilon plays ...st and perhaps even humans. , The study places us ...nome instability that underlie certain environment...
Other Medicine Technology:Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3
3 mm, 130 degree upwards cutting, detachable.
Sabre 180 is a powerful niche generator.
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag.
Medicine Products: